

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京健康(控股)有限公司
Beijing Health (Holdings) Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2389)

**(1) ANNOUNCEMENT IN RELATION TO COMPLIANCE WITH
RULES 13.51B(2) AND 13.51(2)(h) OF THE LISTING RULES
AND
(2) RESIGNATION OF EXECUTIVE DIRECTOR**

**ANNOUNCEMENT IN RELATION TO COMPLIANCE WITH RULES 13.51B(2) AND
13.51(2)(h) OF THE LISTING RULES**

This announcement is made by Beijing Health (Holdings) Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51B(2) and 13.51(2)(h) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Reference is made to the regulatory announcement published by the Stock Exchange on 8 October 2025 (the “**Regulatory Announcement**”) in relation to, among other things, the public censure of Mr. Siu Kin Wai (“**Mr. Siu**”), who is an executive director of the Company. Mr. Siu, a former independent non-executive director of Orient Securities International Holdings Limited (Stock Code: 8001) (“**Orient Securities**”), was publicly censured and was subject to a director unsuitability statement imposed by the GEM Listing Committee of the Stock Exchange (the “**GEM Listing Committee**”) for his breaches of Rules 5.01 and 5.02B(2) of the GEM Listing Rules while serving as a director of Orient Securities. For further details, please refer to the Regulatory Announcement published on the website of the Stock Exchange.

For the avoidance of doubt, the Regulatory Announcement relates to Orient Securities only, and (save for the above regarding Mr. Siu) does not involve any director or senior management of the Company.

Save as disclosed in this announcement, Mr. Siu has confirmed to the Company that there is no other information relating to him that is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and he is not aware of any other matters that need to be brought to the attention of the shareholders of the Company.

To the best of the Board's knowledge, information and belief, the above matter is not related to the affairs of the Company and will not have any material impact on the operations or management of the Company.

RESIGNATION OF EXECUTIVE DIRECTOR

The Board also wishes to announce that, in view of the Stock Exchange's regulatory action against Mr. Siu and the related outcome, Mr. Siu has resigned as an executive director of the Company, with effect from 10 October 2025.

Mr. Siu has confirmed that (i) he has no claim against the Company in relation to his resignation; (ii) he has no disagreement with the Board; and (iii) there are no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its sincere gratitude to Mr. Siu for his contribution to the Company during his tenure of office.

By Order of the Board of
Beijing Health (Holdings) Limited
Zhu Shi Xing
Chairman

Hong Kong, 10 October 2025

As at the date of this announcement, the Board comprises four Executive Directors, namely Mr. Zhu Shi Xing, Mr. Liu Xue Heng, Mr. Gu Shan Chao and Mr. Wang Zheng Chun and four Independent Non-Executive Directors, namely Mr. Tse Man Kit, Keith, Mr. Wu Yong Xin, Mr. Zhang Yun Zhou and Ms. Yang Xiao Yan.